当前位置：
X-MOL 学术
›
Ann. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.
Annals of Oncology ( IF 56.7 ) Pub Date : 2019-12-20 , DOI: 10.1016/j.annonc.2019.12.001 L.-T. Chen , E. Martinelli , A.-L. Cheng , G. Pentheroudakis , S. Qin , G.S. Bhattacharyya , M. Ikeda , H.-Y. Lim , G.F. Ho , S.P. Choo , Z. Ren , H. Malhotra , M. Ueno , B.-Y. Ryoo , T.C. Kiang , D. Tai , A. Vogel , A. Cervantes , S.-N. Lu , C.-J. Yen , Y.-H. Huang , S.-C. Chen , C. Hsu , Y.-C. Shen , J. Tabernero , Y. Yen , C.-H. Hsu , T. Yoshino , J.-Y. Douillard
Annals of Oncology ( IF 56.7 ) Pub Date : 2019-12-20 , DOI: 10.1016/j.annonc.2019.12.001 L.-T. Chen , E. Martinelli , A.-L. Cheng , G. Pentheroudakis , S. Qin , G.S. Bhattacharyya , M. Ikeda , H.-Y. Lim , G.F. Ho , S.P. Choo , Z. Ren , H. Malhotra , M. Ueno , B.-Y. Ryoo , T.C. Kiang , D. Tai , A. Vogel , A. Cervantes , S.-N. Lu , C.-J. Yen , Y.-H. Huang , S.-C. Chen , C. Hsu , Y.-C. Shen , J. Tabernero , Y. Yen , C.-H. Hsu , T. Yoshino , J.-Y. Douillard
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of hepatocellular carcinoma (HCC) was published in 2018, and covered the diagnosis, management, treatment and follow-up of early, intermediate and advanced disease. At the ESMO Asia Meeting in November 2018 it was decided by both the ESMO and the Taiwan Oncology Society (TOS) to convene a special guidelines meeting immediately after the Taiwan Joint Cancer Conference (TJCC) in May 2019 in Taipei. The aim was to adapt the ESMO 2018 guidelines to take into account both the ethnic and the geographic differences in practice associated with the treatment of HCC in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with intermediate and advanced/relapsed HCC representing the oncology societies of Taiwan (TOS), China (CSCO), India (ISMPO) Japan (JSMO), Korea (KSMO), Malaysia (MOS) and Singapore (SSO). The voting was based on scientific evidence, and was independent of the current treatment practices, the drug availability and reimbursement situations in the individual participating Asian countries.
更新日期：2019-12-20
京公网安备 11010802027423号